Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis.

IF 3.9 2区医学 Q1 INFECTIOUS DISEASES Journal of Antimicrobial Chemotherapy Pub Date : 2024-11-13 DOI:10.1093/jac/dkae410

Kunming Pan, Ranyi Li, Yanli Li, Xiaoqiang Ding, Xiaoyu Li, Qianzhou Lv

{"title":"Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis.","authors":"Kunming Pan, Ranyi Li, Yanli Li, Xiaoqiang Ding, Xiaoyu Li, Qianzhou Lv","doi":"10.1093/jac/dkae410","DOIUrl":null,"url":null,"abstract":"Objective: To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs).Methods: PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2-3 AKI.Results: We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2-3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71-3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87-3.29). Also, vancomycin + piperacillin/tazobactam was associated with significantly higher Stage 2-3 AKI risk than vancomycin + cefepime (OR 2.22, 95% CI 1.34-3.62), vancomycin + meropenem (OR1.96, 95% CI 1.22-3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66-4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin + cefepime (OR 2.19, 95% CI 1.38-3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18-1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates.Conclusions: Vancomycin + piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2-3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkae410","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs).

Methods: PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2-3 AKI.

Results: We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2-3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71-3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87-3.29). Also, vancomycin + piperacillin/tazobactam was associated with significantly higher Stage 2-3 AKI risk than vancomycin + cefepime (OR 2.22, 95% CI 1.34-3.62), vancomycin + meropenem (OR1.96, 95% CI 1.22-3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66-4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin + cefepime (OR 2.19, 95% CI 1.38-3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18-1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates.

Conclusions: Vancomycin + piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2-3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

万古霉素联合哌拉西林/他唑巴坦与万古霉素联合其他抗伪内酰胺类药物相比，会增加急性肾损伤的风险：一项系统综述和网络荟萃分析。

目的探讨与其他抗伪内酰胺类药物（BLs）相比，万古霉素加哌拉西林/他唑巴坦是否会增加肾毒性：方法：检索了从开始到2023年10月的PubMed、Embase、Web of Science、Cochrane、CNKI、万方和VIP。主要结果为急性肾损伤（AKI），定义为血清肌酐急性上升 0.3 mg/dL 或 50%，以及严重的 2-3 期 AKI：我们纳入了 70 项研究（76 638 名患者）。网络荟萃分析表明，与万古霉素加头孢吡肟（OR 2.55，95% CI 2-3.28）、万古霉素加美罗培南（OR 2.26，95% CI 1.71-3.02）和万古霉素加其他不常用的BLs（OR 2.47，95% CI 1.87-3.29）相比，万古霉素加哌拉西林/他唑巴坦的AKI风险明显更高。此外，与万古霉素+头孢吡肟（OR 2.22，95% CI 1.34-3.62）、万古霉素+美罗培南（OR 1.96，95% CI 1.22-3.25）和万古霉素+不常用的BLs（OR 2.81，95% CI 1.66-4.91）相比，万古霉素+哌拉西林/他唑巴坦与显著较高的2-3期AKI风险相关。万古霉素+哌拉西林/他唑巴坦在接受透析治疗的发生率、死亡率、住院时间和发生 AKI 的时间方面没有显著差异。对倾向得分匹配研究进行的亚组分析表明，万古霉素+哌拉西林/他唑巴坦的 AKI 发生率明显高于万古霉素+头孢吡肟（OR 2.19，95% CI 1.38-3.47）和万古霉素+美罗培南（OR 1.38，95% CI 1.18-1.60）。对重症患者和儿童进行的亚组分析表明，万古霉素+哌拉西林/他唑巴坦与明显较高的AKI发生率相关：结论：与万古霉素+其他BL相比，万古霉素+哌拉西林/他唑巴坦可显著增加发生AKI和严重2-3期AKI的风险。需要进行更多的前瞻性研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Antimicrobial Chemotherapy 医学-传染病学

CiteScore

9.20

自引率

5.80%

发文量

423

审稿时长

2-4 weeks

期刊介绍： The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.